Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

New Year, New Strategy: Navigating Weight Loss ETFs

BY | ETF Database
10:03 am ET 01/12/26 | 12 VIEWS
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This class of drugs has fundamentally altered the healthcare sector’s growth projections. As the market matures, advisors are increasingly evaluating weight loss ETFs to capture this thematic shift.THNR: The Index-Based Pure PlayThe Amplify Weight Loss Drug & Treatment ETF (THNR B-) offers an index-based entry point into this segment. THNR tracks the VettaFi Weight Loss Drug & Treatment Index, which specifically targets companies engaged in the research, development, and manufacturing of GLP-1 agonists and their alternatives.  The weight loss ETF has a net expense ratio of 0.59% and provides concentrated exposure, with its top 15 holdings recently representing over 90% of the portfolio by weight. This passive structure ensures that the fund remains strictly aligned with the underlying index’s definition of the weight loss market.OZEM & HRTS: Active Management in Weight Loss ETFsIn contrast to the passive approach of THNR, the Roundhill GLP-1 & Weight Loss ETF (OZEM B-) utilizes an active management strategy. This could allow the fund to pivot weightings based on real-time data from clinical trials and FDA regulatory updates. While THNR is rebalanced on a set schedule, OZEM’s managers may potentially adjust exposure depending on manufacturing capacity and emerging competition. However, as of January 9, OZEM and THNR have the same top two holdings – Novo Nordisk and Eli Lilly – and a 61% portfolio overlap by weight, suggesting a simplified passive approach may be suitable in the weight loss ETFs landscape. For advisors seeking a broader medical perspective, the Tema Heart & Health ETF (HRTS ) positions the weight loss trend within a larger cardiology and metabolic diseases framework. Managed by Dr. David Song, HRTS looks beyond obesity to include treatments for diabetes and cardiovascular disease.  HRTS typically holds approximately 45 companies, offering a more diversified portfolio than the pure-play approach of THNR or OZEM. However, this ETF’s specialized active management carries a higher net expense ratio of 0.75% and is lagging the other two weight loss ETFs in year-to-date performance as of January 9. Weight Loss ETFs Comparison for Portfolio ConstructionTHNR provides a transparent, index-based strategy for capturing the growth of the obesity drug market with lower administrative costs. Meanwhile, OZEM offers active agility, and HRTS provides exposure to the comorbid conditions associated with metabolic health.  Weight loss ETFs present a compelling opportunity for investors to capitalize on the long-term thematic growth in the obesity drug market, potentially serving as a high-return satellite position within investment portfolios.  For more news, information, and strategy, visit ETF Trends. VettaFi LLC (“VettaFi”) is the index provider for THNR, for which it receives an index licensing fee. However, THNR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of THNR.`

More Commentary

What Should We Expect From the Fed in 2026?
BY | ETF Database
5:08 am ET 01/12/26 | 28 VIEWS
Dividend ETFs: More Than One Way to Diversify for Income
BY | ETF Database
3:42 am ET 01/12/26 | 123 VIEWS
With Nvidia in the Limelight, Examine This Exciting ETF
BY | ETF Database
7:53 am ET 01/12/26 | 30 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.